Baseline characteristics of the study population
| Baseline characteristics | Study population | Deficient <25 nmol/l | Insufficient 25 nmol/l–74 nmol/l | Sufficient ≥75 nmol/l | p Value |
|---|---|---|---|---|---|
| N | 402 | 201 | 173 | 28 | |
| Age | 67 (58–73) | 67 (58–74) | 67 (60–73) | 65 (58–74) | 0.9 |
| Gender (% male) | 166 (41%) | 71 (35%) | 81 (47%) | 14 (50%) | 0.03 |
| BMI kg/m2 | 25.7 (22.1–29.5) | 25.7 (22.3–28.7) | 25.4 (21.8–29.5) | 27.2 (22.2–32.6) | 0.4 |
| Ethnicity (% Caucasian) | 391 (97.3%) | 193 (96.0%) | 170 (98.3%) | 28 (100%) | 0.3 |
| Comorbidities | |||||
| Chronic cardiac disease | 79 (20%) | 44 (22%) | 32 (19%) | 3 (11%) | 0.3 |
| Chronic renal impairment | 20 (5%) | 14 (7%) | 5 (3%) | 1 (4%) | 0.2 |
| Diabetes mellitus | 52 (13%) | 29 (14%) | 20 (12%) | 3 (11%) | 0.7 |
| Causes of bronchiectasis | |||||
| Idiopathic/post infective | 251 (62%) | 123 (61%) | 112 (65%) | 16 (57%) | 0.7 |
| Previous TB | 70 (17%) | 36 (18%) | 31 (18%) | 3 (11%) | 0.6 |
| Previous ABPA | 35 (9%) | 17 (9%) | 13 (8%) | 5 (18%) | 0.2 |
| Connective tissue disease | 27 (7%) | 14 (7%) | 9 (5%) | 4 (14%) | 0.2 |
| Inflammatory bowel disease | 12 (3%) | 7 (4%) | 5 (3%) | 0 (0%) | 0.6 |
| Others | 7 (2%) | 4 (2%) | 3 (2%) | 0 (0%) | 0.8 |
| Treatment | |||||
| Inhaled corticosteroid use | 166 (41%) | 101 (50%) | 61 (35%) | 4 (14%) | <0.001 |
ABPA, allergic bronchopulmonary aspergillosis; BMI, body mass index; TB, tuberculosis. Data are presented as median (IQR) or N (%).